Impact of imperfect diagnosis in ME/CFS association studies

João Malato 1,2,* , Luís Graça 1 and Nuno Sepúlveda 2,3

- ¹Instituto de Medicina Molecular João Lobo Antunes, Faculty of Medicine, University of Lisbon, Portugal
- ²CEAUL-Centro de Estatística e Aplicações da Universidade de Lisboa, University of Lisbon, Lisbon, Portugal
- ³Faculty of Mathematics and Information Science, Warsaw University of Technology, Warsaw, Poland

Correspondence*: Corresponding Author jmalato@medicina.ulisboa.pt

2 ABSTRACT

1

- The absence of an objective disease biomarker puts studies of Myalgic Encephalomyelitis/Chronic 3 Fatigue Syndrome (ME/CFS) under the curse of imperfect diagnosis. This problem leads to frequent reports that fail to reproduce prior published studies. To address the impact of imperfect diagnosis on the robustness of studies' conclusions, we conducted a simulation study to quantify the statistical power to detect a disease association with a hypothetical binary factor in the 7 presence of imperfect diagnosis. Using the classical case-control design, studies with sample sizes of less than 500 individuals per group could not reach the target power of at least 80% to 10 detect realistic disease associations. We then recreated serological association studies in which the chance of imperfect diagnosis was combined with the probability of misclassifying a binary 11 factor, as it happens in a typical serological association study. In this case, the target power of 80% could only be achieved for studies with more than 1000 individuals per group. Given 13 the current sample sizes of ME/CFS studies, our results suggest that most studies are likely to 14 be underpowered due to imperfect diagnosis alone. To increase reproducibility across studies, we provided some practical recommendations, such as the use of standard case definitions 16 together with multi-centric study designs, and routine reporting of power calculations under a 17 non-negligible chance of misdiagnosis. Our results can also inform the design of future studies under the assumption of misdiagnosis.
- Keywords: misdiagnosis, misclassification, association studies, simulation, power studies, myalgic encephalomyelitis, chronic fatigue
 syndrome

INTRODUCTION

- 22 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease whose patients
- 23 manifest unexplained long-lasting fatigue or post-exertional malaise upon minimal physical or mental
- 24 effort (1, 2). The disease has a sex bias towards women, with a ratio of about two women to one man
- 25 among cases (3). The real burden of the disease remains unknown, but current prevalence estimates range
- 26 from 0.1% to 2.2% (4).
- 27 Given the lack of a biomarker for the disease, the diagnosis of suspected cases is made by a set of key
- 28 symptoms: tagether with the exclusion of known diseases such as multiple selecosis and diabetes. which

could explain fatigue (5). To make the disease diagnosis even more cumbersome, there are multiple case definitions proposed in the literature (6). A possible solution to this problem is to follow expert consensus recommendations for clinical and research practices. In this regard, the European Network on ME/CFS (EUROMENE) suggests the use of the Centre for Disease Control (Fukuda/CDC) criterion (1) and the Canadian Consensus Criteria (CCC) (2) for research purposes (7). In a clinical setting, the ME/CFS diagnosis can also contemplate the Institute of Medicine (IOM) criterion due to its simplicity (8, 9).

The use of different case definitions by clinicians and researchers opens the door to not identifying the same population of patients. As a consequence, it is difficult to ascertain the epidemiology and the real economic costs of the disease (4, 7). Such a discrepancy in case identification has been demonstrated in a study where less than 75% of patients had the same diagnostic outcome across Fukuda/CDC, CCC, and IOM criterion (10). In the same study, data from a symptom assessment questionnaire alone could not completely separate patients diagnosed with ME/CFS from healthy controls and patients with multiple sclerosis. Similar symptoms overlap was found between ME/CFS, multiple sclerosis (11, 12), and rheumatoid arthritis (13); the exclusion of these two autoimmune diseases is, however, part of current ME/CFS diagnostic criteria. In this scenario, current ME/CFS diagnostic criteria are likely to have different sensitivities and are far from 100%.

In general, imperfect diagnostic tests imply the presence of estimation bias in subsequent statistical inference. It also reduces the statistical power to detect true disease associations or the efficiency of estimating the true prevalence (14, 15). These implications are possible explanations for the lack of scientific reproducibility in ME/CFS research. In this regard, Nacul et al. (16) suggested missing important disease associations due to the problem of imperfect ME/CFS diagnosis (i.e., misdiagnosis). However, this study did not include a systematic analysis of the potential impact of misdiagnosis on ME/CFS-related associations. In this scenario, we aimed to investigate the statistical power of hypothetical case-control association studies of ME/CFS in the presence of misdiagnosis. For this purpose, we performed an extensive simulation study under different sample sizes, levels of misdiagnosis, and strength of disease associations. We also investigated the additional impact of sensitivity and specificity associated with serological evaluations that are often performed in ME/CFS (17, 18, 19). Finally, we extended our study to discuss data from two publications (20, 21).

2 STATISTICAL METHODOLOGY

2.1 Statistical formulation of the problem

To study the impact of misclassification, let us assume a classical case-control association study in which diagnosed ME/CFS patients and healthy controls were matched for possible confounders such as age, gender, or body mass index (BMI). The main objective of this study is to investigate a potential association between a candidate causal factor (e.g., a genetic factor or the occurrence of a given infection) and ME/CFS. For simplicity, let us assume that this factor has only two possible outcomes: present versus absent. This is the classical epidemiological situation of a putative risk factor in which individuals can be divided into exposed and non-exposed. The hypothetical data can be summarised by a 2×2 contingency table, whose sampling distribution is the product of two independent Binomial distributions, one Binomial distribution per group,

$$f(x_i|n_i;\theta_i) = \prod_{i=0,1} \binom{n_i}{x_i} \theta_i^{x_i} (1-\theta_i)^{n_i-x_i},$$

- where x_0 and x_1 are the observed frequencies of healthy controls and suspected cases with presence of the
- 68 candidate causal factor, respectively, n_0 and n_1 are the corresponding sample sizes of each group, and θ_0
- and θ_1 are the probabilities for the presence of the candidate causal factor in healthy controls and suspected
- 70 cases, respectively.
- 71 To investigate whether there is evidence for an association between this candidate factor, one can perform
- 72 a hypothesis test in which the null and alternative hypotheses, H_0 and H_1 , are

$$H_0: \theta_0 = \theta_1 \text{ versus } H_1: \theta_0 \neq \theta_1$$
.

73 The same hypotheses can be rewritten in terms of the odds ratio as follows

$$H_0: \frac{\theta_1(1-\theta_0)}{\theta_0(1-\theta_1)} = 1 \text{ versus } H_1: \frac{\theta_1(1-\theta_0)}{\theta_0(1-\theta_1)} \neq 1.$$

- To test these hypotheses, one can use the Pearson's χ^2 test for independence in 2-way contingency tables.
- 75 Using a significance level of 0.05, p-values < 0.05 suggest a rejection of the null hypothesis.
- To study the impact of misdiagnosis on the power of above Pearson's χ^2 test, we considered seven
- 77 simplifying assumptions for the statistical formulation of the problem:
- 78 I. Suspected cases are composed of both apparent and true patients;
- 79 II. The presence of the candidate causal factor is only associated with true patients;
- 80 III. Apparent cases are similar to healthy controls in what the association with the candidate causal factor is concerned;
- 82 IV. The chance of making a ME/CFS misdiagnosis is only dependent on the true clinical status of the cases and not on the confounders;
- V. The association to be detected is independent of disease duration and disease triggers, among other factors occurring during the disease course;
- 86 VI. There is no misdiagnosis (or misclassification) of the true health status of the controls;
- 87 VII. The presence or absence of the candidate causal factor is determined accurately in each individual.
- 88 Assumption VI is invoked to exclude the (unlikely) situation in which healthy controls could include true
- 89 undiagnosed ME/CFS patients. Assumption VII is appropriate for genetic association studies in which the
- 90 genotypic error rate is quantified and typically low (22).
- The above assumptions allow, then, to rewrite the probability of the causal factor being present in
- 92 suspected cases as

$$\theta_1 = \gamma \theta_0 + (1 - \gamma)\theta_1^* \,, \tag{1}$$

- 93 where γ is the misdiagnosis (or misclassification) probability, and θ_1^* is the probability of the candidate
- 94 causal factor being present in true ME/CFS cases. The direct consequence of the above formula is a dilution
- 95 effect of the association operated by the possibility of misdiagnosis. If misdiagnosis could be directly
- 96 observed, the classical 2×2 contingency table could be augmented as in Table 1, where the diagnosed
- 97 cases are divided into apparent and true cases in accordance with assumption I.
- 98 A more-complex statistical situation is to consider the chance of misdiagnosis together with the
- 99 impossibility of determining the presence of the candidate causal factor accurately. This situation is
- 100 the curse of all serological studies on ME/CFS in which the objective is to evaluate the association between

Table 1. Augmented version of the observed 2×2 contingency table in presence of misdiagnosis of ME/CFS cases for a classical case-control association study.

	Controls	ME/CFS-diagnosed cases			
Causal factor		(Apparent)	(True)		
Present Absent	$\begin{matrix} \theta_0 \\ 1 - \theta_0 \end{matrix}$	$ \gamma \theta_0 \\ \gamma (1 - \theta_0) $	$\frac{(1-\gamma)\theta_1^*}{(1-\gamma)(1-\theta_1^*)}$		

- the disease and the presence of antibodies against a given infectious agent (e.g., Epstein-Barr virus (23)).
- In these studies, individuals are deemed seropositive or seronegative based on a threshold in the antibody 102
- distribution. When the estimated antibody distributions for these two populations overlap, the respective 103
- serological classification is subject to uncertainty ruled by the underlying sensitivity and specificity of the 104
- statistical method used (24). The description below follows as if the data at hand were generated from this 105
- type of study. 106
- To model this more complex situation, previous assumption VII is replaced with the two additional 107
- 108 assumptions:
- VII. There are only two possible serological outcomes for each individual: seronegative or seropositive;
- 110 VIII. The sensitivity and specificity of the serological classification are shared across all the individuals.
- The revised assumption VII aims to exclude the situation where the serological classification can 111
- contemplate an indeterminate status due to the laboratory protocol (21) or the presence of multiple
- serological populations (25). Similarly to assumption V for misdiagnosis, the new assumption VIII intends 113
- to disregard the effect of confounders (i.e., age or gender) and disease-related factors (i.e., disease duration 114
- or disease severity) on the performance of the serological classification. 115
- Under the assumptions I–VIII the probability of recording the presence of the candidate causal factor in a 116
- ME/CFS patient can be generalised to 117

$$\theta_1 = \pi_{se} \gamma \theta_0 + (1 - \pi_{sp}) \gamma (1 - \theta_0) + \pi_{se} (1 - \gamma) \theta_1^* + (1 - \pi_{sp}) (1 - \gamma) (1 - \theta_1^*), \qquad (2)$$

- where π_{se} and π_{sp} are sensitivity and specificity for the serological classification, respectively. Note that,
- when $\pi_{se} = \pi_{sp} = 1$ (perfect serological testing), the above formula converts to equation (1). Table 1 can 119
- thus be further augmented by including the true serological status of the individuals (Table 2).

Table 2. Augmented version of the observable 2×2 frequency Table in the case-control association study with possible misdiagnosis of ME/CFS cases and misclassification of the true serological status (seropositive, S^+ , and seronegative, S^-).

Estimated	True	Controls	ME/CFS-diagnosed cases		
Serological status	serological status	Controls	(Apparent)	(True)	
<u>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</u>	S^+	$\pi_{se}\theta_0$	$\pi_{se}\gamma\theta_0$	$\pi_{se}(1-\gamma)\theta_1^*$	
\mathcal{S}	S^-	$(1-\pi_{sp})(1-\theta_0)$	$(1-\pi_{sp})\gamma(1-\theta_0)$	$(1-\pi_{sp})(1-\gamma)(1-\theta_1^*)$	
S^-	S^+	$(1-\pi_{se})\theta_0$	$(1-\pi_{se})\gamma\theta_0$	$(1 - \pi_{se})(1 - \gamma)\theta_1^*$	
S	S^-	$\pi_{sp}(1-\theta_0)$	$\pi_{sp}\gamma(1-\theta_0)$	$\pi_{sp}(1-\gamma)(1-\theta_1^*)$	

129 130

131

132 133

134135

136

137

138 139

140

156

2.2 Simulation study

To investigate the impact of both misdiagnosis scenarios on detecting an association between a candidate causal factor and ME/CFS, we performed a comprehensive simulation study assuming matched sample sizes for ME/CFS patients and healthy controls ($n_0 = n_1$). We considered the following sample sizes per study group: 100, 250, 500, 1000, 2500, and 5000. This choice of sample size is probably optimistic for ME/CFS research, given the sample sizes (mean = 86.2, range = 16-300 for ME/CFS group) reported in immune marker studies conducted in Europe (26).

To parameterise the simulation study, we first specified the association between the candidate causal factor and true ME/CFS patients by the odds ratio (hereafter denoted as Δ_T) and the probability of the presence of the causal candidate factor in healthy controls (θ_0). We considered $\Delta_T \in \{1.25, 1.5, 2, 3, 5, 10\}$, whose values ranged from weak to strong associations. Given the lack of disease-specific biomarkers, it is expected that the putative associations to be detected should not be too strong. However, the simulation of strong associations is important to assess what to expect under an optimistic scenario. In addition, we specified $\theta_0 \in \{0.05, 0.1, 0.25, 0.5\}$. In the case of candidate gene scenarios, θ_0 could represent the minor allele frequency of a given single nucleotide variant in the healthy population. Combining the values of θ_0 together with the ones specified for Δ_T , we could study the impact of misdiagnosis on detecting whether ME/CFS follows the "common disease, rare variant hypothesis" or the "common disease, common variant hypothesis". For these two contrasting hypotheses, a common disease could be the result of either multiple rare genetic factors with a high penetrance or many common genetic variants with low penetrance (27, 28). Having θ_0 and Δ_T fixed in the respective values, we can determine the value of θ_1^* as follows

$$\theta_1^* = \frac{\theta_0 \Delta_T}{1 + \theta_0 (\Delta_T - 1)} \,. \tag{3}$$

141 With respect to the probability of misdiagnosis, γ , we allowed this parameter to vary from 0 (all cases were 142 correctly diagnosed) to 1 (all cases were incorrectly diagnosed) with a lag of 0.01.

To simulate data from the second misdiagnosis scenario, we considered fixed parameters $\Delta_T = 3$ and $\theta_0 = 0.25$. For parameters π_{se} and π_{sp} , we considered all possible combinations of 0.80, 0.90, 0.925, 0.975, and 1.0, where $\pi_{se} = \pi_{sp} = 1$ corresponded to the first scenario.

For each misdiagnosis scenario, parameter set, and sample size, we simulated 10,000 datasets to estimate 146 the power of rejecting H_0 when the possibility of misdiagnosis was ignored. A detailed description of 147 the simulation procedure can be found elsewhere (10). In each data set, we rejected H_0 if the p-value of 148 the Pearson's χ^2 test was less than the usual level of significance, $\alpha=0.05$. The power of the study was 149 estimated as the overall proportion of simulated data sets in which H_0 was rejected. To better understand 150 the practical implications of the simulation results, we specified a target power of at least 80% for the 151 152 probability of rejecting the null hypothesis in favour of the alternative hypothesis, given that the latter was 153 true. The term used for this target power is generally denoted as $1-\beta$, where β represents the probability of incorrectly failing to reject H_0 (Type II error). A target value of 80% suggests that a true association is 154 very likely to be reproducible in a follow-up study. 155

2.3 Application to two ME/CFS studies

We also studied the impact of misdiagnosis on available data from a candidate gene association study and an immunological evaluation study. The first study recruited 201 self-reported healthy controls and 305

- ME/CFS patients whose symptoms complied with CCC (20). All participants were genotyped for 5 SNPs previously associated with autoimmune diseases:
- rs2476601, tyrosine phosphatase non-receptor type 22 (*PTPN*22);
- rs3087243, cytotoxic T-lymphocyte-associated protein 4 (*CTLA4*);
- rs1800629 and rs1799724, tumor necrosis factor (*TNF*);
- rs3807306, interferon regulatory factor 5 (*IRF5*).
- 165 The study found significant associations of rs2476601 (PTPN22) and rs3087243 (CTLA4) with ME/CFS
- 166 patients potentially triggered by an acute infection.
- The second study encompassed data of 251 patients and 107 healthy controls from the UK ME/CFS
- 168 biobank (21). Patients complied with either Fukuda/CDC or CCC. The original objective of this study
- 169 was to perform a detailed comparison between these two groups in terms of immune-cell data. Here,
- 170 we focused on data of antibody positivity related to six different herpesviruses: human cytomegalovirus
- 171 (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1 and 2 (HSV1 and HSV2), varicella-zoster virus
- 172 (VZV), and human herpesvirus (HHV6). Note that, for each virus, antibody positivity was determined by a
- 173 cut-off value as recommended by the manufacturers of the serological kits. However, another re-analysis of
- 174 the same data provided evidence for an overlap between the antibody distribution of hypothetical antibody-
- 175 negative and antibody-positive populations (24). Therefore, besides the potential ME/CFS misdiagnosis,
- 176 the subsequent antibody classification could also be affected by misclassification.
- 177 In both studies, we estimated the power of detecting an association as a function of misdiagnosis
- 178 probability, γ , using simulated data generated from the reported associations, as explained later.

3 RESULTS

179

3.1 Simulation study: impact of ME/CFS misdiagnosis

- The power to detect an association with ME/CFS decreased with the misdiagnosis probability (Figure 1
- and Figure 2). The maximum power was achieved when all the patients were assumed to be true cases
- 182 $(\gamma = 0)$, that is, when there was no dilution effect of the true association to be detected. In the other
- 183 extreme, when all the patients were assumed to be apparent cases ($\gamma = 1$), the corresponding power was
- 184 equal to the significance level set up for the analysis ($\alpha = 0.05$). This result was a direct consequence of
- assumption III, in which the misdiagnosed cases were deemed identical to healthy controls in what the
- 186 association with the candidate causal factor was concerned.
- As expected, the most optimistic scenarios were associated with $\Delta_T = 5$ or 10 (i.e., strong associations
- 188 between the candidate causal factor and true ME/CFS cases). In these scenarios, it was possible to find
- a maximum misdiagnosis probability in which the target power of 80% was achieved irrespective of
- 190 the sample size and the probability of the causal factor being present in healthy controls (Table 3). For
- 191 $\Delta_T = 10$, a misdiagnosis probability of 0.53 was sufficient to ensure the desired power for sample sizes
- 192 greater of equal to 100 individuals per study group ($n_i \ge 100$), irrespective of θ_0 . This minimum probability
- 193 reduced to 0.24 for $\Delta_T = 5$. That is, when the association between the candidate causal factor and true
- 194 ME/CFS cases was strong, the chance of missing its diagnosis could only occur if the chance of ME/CFS
- 195 misdiagnosis was simultaneously high. Therefore, if the "common disease, rare variant" hypothesis holds
- 196 true in ME/CFS, it is very likely to be detected by genome-wide association studies.

198

199 200

201

202 203

204

205 206

207

208

209

210

211

213

215

216

217 218

219

220

232

233

234 235

236

237

Similar optimistic scenarios were observed for sample sizes of 2500 and 5000 individuals per study group with the exception of the case of lowest $\Delta_T = 1.25$. Combining these large sample sizes with strong associations between the candidate causal factor and the true ME/CFS cases, the target power could only not be achieved when almost all the cases were misdiagnosed (with misdiagnosis probability greater than or equal to 0.88).

The most pessimist scenarios were associated with either $\Delta_T = 1.25, 1.5$ or $n_0 = n_1 = 100$. When $\Delta_T = 1.25$, the sample size had to increase to 2500 or 5000 individuals per group in order to achieve the desired target power. Therefore, for this weak association, the likelihood of finding reproducible results was very low, even under the assumption of a perfect diagnosis. As a consequence, testing the "common disease, common variant hypothesis" in ME/CFS is likely to fail in future genetic associations. Finally, the case of $n_0 = n_1 = 100$ was particularly problematic given that it was not possible to find any value misdiagnosis probability in which the desired power could be achieved for $\Delta_T \leq 2$ (Figure 1).

Simulation study: impact of ME/CFS misdiagnosis and misclassification on the candidate causal factor

We then simulated data of a hypothetical association study in which there were both imperfect diagnoses and misclassification of the candidate causal factor (Figure 2). As explained earlier in this paper, this 212 scenario is the curse of any serological association study in ME/CFS, given the estimation of seropositivity 214 of each individual could be affected by the sensitivity and specificity associated with the classification rule used. At this point, it was clear that for values of $\Delta_T = 1.25$, 1.5, and 2, the desired power was not often achieved for sample sizes smaller than 500 individuals per group in the case of perfect classification of the causal factor. Therefore, the additional assumption of imperfect classification of the candidate causal factor would make previously estimated power even worse. Because of that, we only performed our simulation study on the more optimistic scenario in which $\Delta_T = 3$ (Table 4).

Application to data from two ME/CFS studies

We illustrated the problem of misdiagnosis in data from two ME/CFS studies (20, 21). We started with 221 data from a candidate gene association study (20). In this study, some genetic associations were only found 222 significant when comparing healthy controls to ME/CFS patients with an infectious disease trigger onset 223 (Table 5). The estimated allele-related odds ratios varied from 0.84 [95%CI = (0.56, 1.27)] (rs1799724, 224 225 TNF_2) to 1.63 [95%CI = (1.04, 2.55)] (rs2476601, *PTPN22*). In our re-analysis, we investigated the impact 226 of misdiagnosis if a replication study were conducted in the same population. In line with the original study, no genotyping errors were assumed for the genetic data. The reported odds ratios were assumed to 227 228 be the true ones for the population and data were simulated with the same number of reported alleles as in the original study. A description of the simulation procedure can be found elsewhere (10). Similarly 229 to the previous sections, we estimated the probability of rejecting H_0 as a function of the misdiagnosis 230 probability. 231

Again, the estimated probability of rejecting H_0 decreased with the misdiagnosis probability (Figure 3A). More importantly, when the chance of misdiagnosis was low ($\gamma < 0.09$), it was possible to obtain the target power of 80% for the allele association reported for rs3087243 in CTLA4. Therefore, the target power cannot be ensured for $\gamma > 0.09$. For the remaining SNPs, the target power was never achieved irrespective of the misdiagnosis probability. This is particularly problematic for rs2476601 in PTPN22 whose association was reported to be significant at a 0.05 significance level. For this SNP, a chance of

241

242

243

Table 3. Maximum values of misdiagnosis probability γ that still ensured the power of at least 80% to reject the null hypothesis of lack of association at different values of true odds ratio, Δ_T , risk factor probability on healthy controls and false positive cases, θ_0 , and sample sizes, n_i , i=(0,1). Cells with no value indicate that the desired power could not be reached using the respective parameter combination, even when considering a perfect diagnostic scenario ($\gamma=0$).

Δ_T θ_0	0.05	0.1	0.25	0.5	n_i
10 5 3 2 1.5 1.25	0.59 0.24 - - -	0.65 0.43 0.02 - -	0.64 0.50 0.25 - -	0.53 0.42 0.23	100
10 5 3 2 1.5 1.25	0.77 0.56 0.20 - -	0.79 0.66 0.41 - -	0.77 0.69 0.53 0.23	0.70 0.63 0.50 0.26	250
10 5 3 2 1.5 1.25	0.84 0.70 0.47 - -	0.86 0.76 0.60 0.27	0.84 0.78 0.67 0.46 0.04	0.78 0.73 0.65 0.47 0.13	500
10 5 3 2 1.5 1.25	0.89 0.80 0.64 0.32	0.90 0.84 0.72 0.50 0.05	0.89 0.85 0.77 0.62 0.32	0.84 0.81 0.75 0.62 0.38	1000
10 5 3 2 1.5 1.25	0.93 0.88 0.78 0.58 0.18	0.94 0.90 0.83 0.69 0.42	0.93 0.90 0.85 0.76 0.58 0.20	0.90 0.88 0.84 0.76 0.59 0.28	2500
10 5 3 2 1.5 1.25	0.95 0.91 0.84 0.71 0.44	0.95 0.93 0.88 0.78 0.59 0.20	0.95 0.93 0.90 0.83 0.70 0.44	0.93 0.91 0.88 0.83 0.72 0.49	5000

approximately 10% misdiagnosis deemed a power of about 50%, conceptually making the replication of this result equivalent to flipping a coin.

The second study referred to putative associations of 6 herpes virus infections with ME/CFS using serological data (21). In these data, all individuals were classified as seronegative or seropositive for each antibody used. Under the assumption of perfect serological classification and diagnosis, the associations of these serological data with severely affected ME/CFS patients ranged from 0.65 [95%CI = (0.21, 1.97)] to

248249

250

251

252

253

254

255

Table 4. Maximum values of misdiagnosis probability γ that still ensures a power of rejecting the null hypotheses of at least 80% for $\Delta_T=3$ and $\theta_0=0.25$, where π_{se} and π_{sp} represent sensitivity and specificity associated with the classification of the candidate, respectively. See Table 3 for more information.

π_{sp} π_{se}	1	0.975	0.925	0.9	0.8	n
1	0.25	0.23	0.20	0.19	0.11	
0.975	0.22	0.20	0.17	0.15	0.06	
0.925	0.17	0.14	0.09	0.08	_	100
0.9	0.13	0.11	0.07	0.04	_	100
0.8	0.03	_	_	_	_	
1	0.53	0.52	0.51	0.50	0.45	
0.975	0.51	0.50	0.48	0.47	0.42	
0.925	0.47	0.46	0.43	0.42	0.36	250
0.9	0.45	0.43	0.41	0.39	0.32	230
0.8	0.38	0.36	0.31	0.29	0.18	
1	0.67	0.67	0.66	0.65	0.62	
0.975	0.66	0.65	0.64	0.63	0.59	
0.925	0.63	0.62	0.60	0.59	0.55	500
0.9	0.61	0.61	0.59	0.57	0.52	300
0.8	0.56	0.54	0.51	0.50	0.42	
1	0.77	0.77	0.76	0.75	0.73	
0.975	0.76	0.75	0.74	0.74	0.72	
0.925	0.74	0.73	0.72	0.71	0.68	1000
0.9	0.73	0.72	0.71	0.70	0.67	1000
0.8	0.68	0.67	0.65	0.64	0.59	
1	0.85	0.85	0.85	0.84	0.83	
0.975	0.85	0.85	0.84	0.84	0.82	
0.925	0.84	0.83	0.82	0.82	0.80	2500
0.9	0.83	0.82	0.81	0.81	0.79	2300
0.8	0.80	0.79	0.78	0.78	0.74	
1	0.90	0.90	0.89	0.89	0.88	
0.975	0.89	0.89	0.89	0.88	0.87	
0.925	0.88	0.88	0.87	0.87	0.86	5000
0.9	0.88	0.87	0.87	0.87	0.85	5000
0.8	0.86	0.85	0.84	0.84	0.81	

244 1.60 [95%CI = (0.83, 3.09)] for Epstein-Barr virus (EBV) and Herpes simplex virus 1 (HSV1), respectively 245 (Table 6). For this case, none of the associations was deemed significant at the usual significance level of 246 5% according to the original study (p-values ≥ 0.16).

The original serological classification was based on a cut-off in the antibody levels determined by the 2σ -rule. In general, this cut-off is defined by the mean plus twice the standard deviation of a known seronegative population. Under the assumption of a normal distribution for the seronegative population, the expected specificity of the serological specificity is approximately 0.975 (24). We assumed this value for π_{sp} . For simplicity, we assumed $\pi_{se} = \pi_{sp}$. Again, we simulated data from this scenario as the original study and estimated the probability of rejecting H_0 as a function of the misdiagnosis probability.

In this study, it was not possible to reach the desired power of 80% to reject H_0 for any of the antibodies (Figure 3B). The best case was observed for the data of antibodies against HSV1. In this case, the maximum power was approximately 0.50 in the absence of misdiagnosis. This power dropped to 0.30 when $\gamma = 0.25$.

Table 5. Reported associations of a candidate gene association study (20) where $\hat{\theta}_0$ represents the frequencies of the non-reference allele for healthy controls and $\hat{\Delta}_T$ is the odds ratio of these allele frequencies when comparing ME/CFS patients with an infectious disease trigger to healthy controls. P-values are associated with the Pearson's χ^2 test for 2×2 contingency tables.

SNP	Gene	$\hat{ heta}_0$	$\hat{\Delta}_T$	$\operatorname{CI}(\hat{\Delta}_T)$	p-value
	CTLA4			(1.17, 2.03)	0.002
rs2476601				(1.04, 2.55)	0.033
	TNF_2		0.84	, ,	0.409
rs1800629	TNF_1			(0.61, 1.30)	0.551
rs3807306	IKF5	0.51	0.94	(0.72, 1.22)	0.637

Table 6. Summary of serological findings from (21), where $\hat{\theta}_0$ represents the seroprevalence of healthy controls and $\hat{\Delta}_T$ refers to the odds ratio for being seropositive when comparing severely-affected ME/CFS patients with healthy controls. The 95% CI $(\hat{\Delta}_T)$ P-values are associated with the Pearson's χ^2 test for 2×2 contingency tables.

Herpes virus	$\hat{ heta}_0$	$\hat{\Delta}_T$	95% CI ($\hat{\Delta}_T$)	p-value
Herpes simplex virus 1 Herpes simplex virus 2 Epstein-Barr virus Cytomegalovirus Varicella-Zoster virus Human Herpesvirus-6	0.42	1.60	(0.83, 3.09)	0.163
	0.34	1.36	(0.69, 2.66)	0.377
	0.93	0.65	(0.21, 1.97)	0.442
	0.37	0.84	(0.42, 1.67)	0.613
	0.97	0.75	(0.12, 4.63)	0.757
	0.95	1.27	(0.24, 6.79)	0.776

For the remaining cases, the power was almost exclusively less than 0.20. This could partially be explained by the fact that θ_0 is higher than 0.93 for antibody data related to EBV, HHV6, and VZV. Therefore, the chance of finding a significant association is meagre if the study were to be repeated in the same population and under the same conditions.

4 DISCUSSION

This study showed the impact of disease misdiagnosis on the reproducibility of associations from a given ME/CFS study. This impact encompasses non-trivial combinations of sample size, effect size (or strength of association), and misdiagnosis probability, in general, plus specificity/sensitivity in the case of serological association studies. In this regard, our simulation study showed that strong associations with ME/CFS can be detected with reasonable power even when the probability of misdiagnosis is not negligible. However, strong associations are unlikely to be detected in ME/CFS, given the persistent difficulty in finding reproducible biomarkers (26) and the lack of consistently significant results reported by different genetic association studies of the disease (29, 30, 31, 32). In addition, even if these strong associations could be detected, the respective estimates should be taken as an underestimation of the true ones due to the presence of apparent cases. In other words, the assumption of misdiagnosis implies that the association estimates are intrinsically biased and, therefore, should be corrected, as done in the estimation of disease prevalence in the presence of imperfect diagnostic tests (15). In general, the chance of misdiagnosis (or misclassification) brings a situation of overparameterization of the respective statistical analysis, where the misdiagnosis probability cannot be estimated from the data directly. To deal with this situation, there

276

277278

279

280

281 282

283

284 285

286

287 288

289 290

291

292

293

294295

296

297

298

299

300

301

302

303

304

305

306 307

308

309

310

311

312 313

314

315 316

317

318

are non-trivial solutions in the statistical literature (33, 34). However, the discussion about these advanced solutions was out of the scope of this study.

It was also clear that sufficiently large sample sizes can compensate for the reduction in power due to misdiagnosis and misclassification of a potential causal factor. In this regard, a minimum sample size of 500 individuals per group minimises the negative impact of misdiagnosis alone on power. This minimum sample size required an increase towards 1000 individuals per group when the misdiagnosis probability is combined with the misclassification probabilities associated with the potential causal factor. In general, the sampling of such large numbers of individuals is challenging, but is becoming feasible in common, well-recognised, and highly-funded diseases, such as cancer, cardiovascular diseases (35), and autoimmune disorders (36, 37). However, for ME/CFS, where the research is affected by limited funding and poor societal recognition (38), the recruitment of large numbers of patients might be problematic. A possible solution to this problem is to use a collection of samples available from existing biobanks. In this regard, the UK ME/CFS Biobank is fully dedicated to the advancement and acceleration of ME/CFS research. It comprises biological samples of more than 500 individuals, including ME/CFS patients, healthy controls, and patients with multiple sclerosis as an additional control group (39). The strength of this biobank is a detailed characterisation of all the participants and the use of current standards for ME/CFS diagnosis. However, this biobank only contemplates around 250 ME/CFS patients. As an alternative, the UK Biobank has been reported to include 1890 to 2105 ME/CFS cases (30, 32). However, it is unclear the accuracy of the respective data given that ME/CFS diagnosis was self-reported by participants. In this scenario, the most obvious solution to increase the sample size is to conduct multi-centric studies, as suggested by the European ME/CFS Biomarker Landscape project (26). Such a research strategy has already been adopted by a recent genetic association study that contemplated Norwegian, Danish, and British cohorts at different stages of the analysis (32). Notwithstanding their attractiveness and potential impact on biomarker discovery, multi-centric studies require considerable funding, robust research protocols and ethics, and strong compliance among the participating sites. In this scenario, the major challenge of these studies consists in the fact that ME/CFS research is currently underfunded (40, 41). However, there is hope emerging from initiatives such as EUROMENE and the US Clinician Coalition, whose objective is to promote and foster collaboration and shared resources among their members. In addition, the similarity between long-Covid and ME/CFS highlighted the need to increase research funding on these conditions to mitigate their economic costs in the future (42). Therefore, large multi-centric studies in ME/CFS are expected to become a routine research practice in the future.

The potential misclassification of a binary causal factor is often neglected in the analysis of both genetic and serological association studies of ME/CFS. In previous studies, this neglect does not seem problematic because estimated genotype error rates are below 1% (43). However, higher genotype error rates can be obtained for rare genetic markers (44), and genetic markers with minor allele frequencies less than 0.01 or 0.05 are typically excluded from genetic association studies of ME/CFS (22, 32, 45). The parameterization of our simulation study (i.e., $\theta_0 > 0.05$) is then in line with this research practice and, thus, the respective findings are directly applicable for understanding the reproducibility of current genetic association studies of ME/CFS. Within this scenario, Dibble et al. (31) advocated for conducting well-powered studies with large cohort sizes. In the present context, such a suggestion is not only important to detect common variants with low genetic effects, but also to minimise the impact of misdiagnosis on the underlying power function, as demonstrated by the present study. In the case of serological association studies, the serological status of each individual can only be determined statistically. Generally, when the antibody distributions of the underlying seronegative or seropositive populations do not overlap with each other, the serological status of each individual can be determined almost perfectly. In practice, serological data of

herpesviruses from the UK ME/CFS Biobank showed that the distributions of these serological populations can overlap with each other, as demonstrated by data related to herpesviruses serology from the UK ME/CFS Biobank (19). However, current serological association studies do not report the sensitivity and specificity of the corresponding serological classification rule and, therefore, it is unclear how these misclassification parameters vary from one study to another and how they affect the power of detecting underlying associations. The situation is problematic given that these studies are also affected by the high seroprevalence of many viruses in the population, the possibility of batch and laboratory effects, differences in the antigens used, interactions between serological outcomes, and typical confounders, such as gender and age, and the use of different criteria for seropositivity estimation (19, 46, 47). Therefore, it is imperative the reporting of the uncertainty associated with the serological classification rule in future studies.

In this study, we assumed independence between disease association and possible confounding factors. In practice, this assumption might not always be true, given the evidence that age, gender, or exposure to a given infectious agent can influence the respective findings (19, 48). Hence, the above assumption is more appropriate for interpreting studies in which individuals are sampled from a specific combination of confounding factors. Such a sampling strategy is particularly adopted in DNA methylation studies in which adult women with matched age and BMI are the target population (49).

Furthermore, we assumed no misdiagnosis of healthy controls. This assumption deserves a comment in light of current data and research practices. On the one hand, ME/CFS patients and some healthy controls share the same symptoms and level of fatigue (10, 50). On the other hand, studies such as Loebel et al. (17) and Szklarski et al. (48) recruited healthy individuals solely based on self-reporting. Such recruiting strategy, although reducing research costs, increases the chance of sampling asymptomatic but unhealthy individuals. A similar problem can be expected in Kaushik (51), Johnston et al. (52), and Lande et al. (53), using control samples from blood donors. In Herrera et al. (29), Blauensteiner et al. (54), de Vega et al. (55), and Trivedi et al. (56), both asymptomatic non-obese and obese individuals were recruited for subsequent matching with ME/CFS patients. However, some of these individuals can be seen as cases of undiagnosed metabolic syndrome (57, 58, 59). Recruiting these individuals is particularly problematic given the association of metabolic syndrome with ME/CFS (60). With all of the evidence, healthy controls could also be divided into true and apparent controls, thus further reducing the statistical power to detect a putative disease association. Therefore, the most general assumption is to consider the possibility in which undiagnosed patients of ME/CFS or any other disease can be mistakenly recruited as healthy controls. To avoid this situation, the health status of putative controls should also be routinely confirmed with lab testing.

We formulated the statistical problem in terms of ME/CFS misdiagnosis, considering the suspected ME/CFS cohort to be composed of misdiagnosed and true patients. From a modelling standpoint, our formulation can be reframed as a related problem in which the ME/CFS group can be divided into two subgroups of patients, and the association to be detected is only present in one of these subgroups. This alternative formulation follows the idea that ME/CFS encompasses multiple disease subtypes (61). However, we should be cautious when interpreting our results in this alternative scenario. First, the assumption of only two disease subgroups seems overly simplistic, given that it was suggested more than seven genomic subtypes for the disease (62, 63). Second, these potential subtypes might overlap with each other, given that no clear stratification of patients could be identified using symptoms' data (10). Hence, the membership of each patient to a given disease subtype might be probabilistic in nature. However, this situation is more complex and was not captured by the presented mathematical formulation.

362 In summary, this study discusses the reproducibility of ME/CFS studies in terms of disease misdiagnosis. Given the absence of an objective biomarker for disease diagnosis, the most obvious recommendations 363 are: (i) to use recommended case definitions for ME/CFS diagnosis; (ii) to increase cohort sizes using 364 multi-centric studies; and (iii) to confirm the health status of putative controls. These recommendations 365 366 combined are likely to minimise the impact of misdiagnosis of both patients and controls on the disease associations to be detected. A final recommendation is to perform post-hoc power calculations as a function 367 of misdiagnosis probability in order to quantify the likelihood of a reproducible finding in the presence of 368 imperfect diagnosis of ME/CFS. 369

CONFLICT OF INTEREST STATEMENT

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

- 372 JM and NS conceived and designed the analysis. JM performed the computer simulations, statistical
- analysis, and wrote the initial manuscripts. All authors participated actively in the discussion of the results.
- 374 All authors have read, revised, and approved the final version of the manuscript.

FUNDING

- 375 JM acknowledges funding from Fundação para a Ciência e Tecnologia, Portugal (grant ref.
- 376 SFRH/BD/149758/2019). NS acknowledges funding from the Fundação para a Ciência e Tecnologia,
- Portugal (ref. UIDB/00006/2020), and the Polish National Agency for Academic Exchange, Poland (ref.
- 378 PPN/ULM/2020/1/00069/U/00001).

ACKNOWLEDGMENTS

- 379 JM would like to thank Prof. Przemysław Biecek and the MI² DataLab group at Faculty of Mathematics
- and Information Science, Warsaw University of Technology, Warsaw, Poland, for their support during part
- 381 of the analysis and discussion of this article.

DATA AVAILABILITY STATEMENT

- 382 All simulations and analyses were done using R statistical software, version 4.1.0 (64).
- 383 The source code and datasets generated can be found in the GitHub public repository
- 384 (https://github.com/jtmalato/misclassification-simulations).

REFERENCES

- Tukuda K, Strausm SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome:
 A comprehensive approach to its definition and study. *Annals of Internal Medicine* 121 (1994) 953.
- doi:10.7326/0003-4819-121-12-199412150-00009.
- 2. Carruthers BM, Jain AK, Meirleir KLD, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome. *Journal of Chronic Fatigue Syndrome* 11 (2003) 7–115.
- 390 doi:10.1300/j092v11n01_02.

- 39. Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *Journal of Translational Medicine* **18** (2020). doi:10.1186/s12967-020-02269-0.
- 4. Estévez-López F, Mudie K, Wang-Steverding X, Bakken IJ, Ivanovs A, Castro-Marrero J, et al. Systematic review of the epidemiological burden of myalgic encephalomyelitis/chronic fatigue syndrome across Europe: Current evidence and EUROMENE research recommendations for epidemiology. *Journal of Clinical Medicine* 9 (2020) 1557. doi:10.3390/jcm9051557.
- 5. Smith MEB, Nelson HD, Haney E, Pappas M, Daeges M, Wasson N, et al. Diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome. Tech. rep. (2014). doi:10.23970/ahrqepcerta219.
- 6. Brurberg KG, Fønhus MS, Larun L, Flottorp S, Malterud K. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. *BMJ Open* 4 (2014) e003973.
 doi:10.1136/bmjopen-2013-003973.
- 7. Pheby DF, Araja D, Berkis U, Brenna E, Cullinan J, de Korwin JD, et al. The development of a consistent Europe-wide approach to investigating the economic impact of myalgic encephalomyelitis (ME/CFS): A report from the European network on ME/CFS (EUROMENE). *Healthcare* 8 (2020) 88. doi:10.3390/healthcare8020088.
- **8**. Institute of Medicine. *Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness* (Washington, DC: The National Academies Press) (2015). doi:10.17226/19012.
- 9. Nacul L, Authier FJ, Scheibenbogen C, Lorusso L, Helland IB, Martin JA, et al. European network
 on myalgic encephalomyelitis/chronic fatigue syndrome (EUROMENE): Expert consensus on the
 diagnosis, service provision, and care of people with ME/CFS in europe. *Medicina* 57 (2021) 510.
- doi:10.3390/medicina57050510.
- **10**. Malato J, Graça L, Nacul L, Lacerda E, Sepúlveda N. Statistical challenges of investigating a disease with a complex diagnosis. *medRxiv* (2021). doi:10.1101/2021.03.19.21253905.
- 415 11. Morris G, Maes M. Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis
 416 disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and
- 417 neuroimmune characteristics. *BMC Medicine* **11** (2013). doi:10.1186/1741-7015-11-205.
- 418 **12**. Gaber TAZK, Oo WW, Ringrose H. Multiple sclerosis/chronic fatigue syndrome overlap: When two common disorders collide. *NeuroRehabilitation* **35** (2014) 529–534. doi:10.3233/NRE-141146.
- 13. Ali S, Matcham F, Irving K, Chalder T. Fatigue and psychosocial variables in autoimmune rheumatic disease and chronic fatigue syndrome: A cross-sectional comparison. *Journal of Psychosomatic Research* 92 (2017) 1–8. doi:https://doi.org/10.1016/j.jpsychores.2016.11.002.
- **14**. Greenland S. Basic methods for sensitivity analysis of biases. *International Journal of Epidemiology* **25** (1996) 1107–1116. doi:https://doi.org/10.1093/ije/25.6.1107-a.
- **15**. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. *American Journal of Epidemiology* **107** (1978) 71–76. doi:10.1093/oxfordjournals.aje.a112510.
- 16. Nacul L, Lacerda EM, Kingdon CC, Curran H, Bowman EW. How have selection bias and disease misclassification undermined the validity of myalgic encephalomyelitis/chronic fatigue syndrome studies? *Journal of Health Psychology* 24 (2017) 1765–1769. doi:10.1177/1359105317695803.
- 17. Loebel M, Eckey M, Sotzny F, Hahn E, Bauer S, Grabowski P, et al. Serological profiling of the EBV immune response in chronic fatigue syndrome using a peptide microarray. *PLOS ONE* 12 (2017) e0179124. doi:10.1371/journal.pone.0179124.
- 18. Shikova E, Reshkova V, ntoniya Kumanova, Raleva S, Alexandrova D, Capo N, et al. Cytomegalovirus, epstein-barr virus, and human herpesvirus-6 infections in patients with myalgic

- encephalomyelitis/chronic fatigue syndrome. *Journal of Medical Virology* (2020). doi:10.1002/jmv. 25744.
- 437 19. Domingues TD, Grabowska AD, Lee JS, Ameijeiras-Alonso J, Westermeier F, Scheibenbogen C,
- et al. Herpesviruses serology distinguishes different subgroups of patients from the United Kingdom
- 439 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Biobank. Frontiers in Medicine 8 (2021).
- doi:10.3389/fmed.2021.686736.
- 20. Steiner S, Becker SC, Hartwig J, Sotzny F, Lorenz S, Bauer S, et al. Autoimmunity-related risk variants
- in PTPN22 and CTLA4 are associated with ME/CFS with infectious onset. Frontiers in Immunology
- 443 **11** (2020). doi:10.3389/fimmu.2020.00578.
- 21. Cliff JM, King EC, Lee JS, Sepúlveda N, Wolf AS, Kingdon C, et al. Cellular immune function in
- myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Frontiers in Immunology 10 (2019).
- doi:10.3389/fimmu.2019.00796.
- 22. Grabowska AD, Lacerda EM, Nacul L, Sepúlveda N. Review of the quality control checks performed
- by current genome-wide and targeted-genome association studies on myalgic encephalomyelitis/chronic
- fatigue syndrome. Frontiers in Pediatrics 8 (2020). doi:10.3389/fped.2020.00293.
- 450 23. Ruiz-Pablos M, Paiva B, Montero-Mateo R, Garcia N, Zabaleta A. Epstein-Barr virus and the origin
- of myalgic encephalomyelitis or chronic fatigue syndrome. Frontiers in Immunology 12 (2021).
- 452 doi:10.3389/fimmu.2021.656797.
- **24**. Domingues TD, Mouriño H, Sepúlveda N. Analysis of antibody data using finite mixture models based on scale mixtures of skew-normal distributions. *medRxiv* (2021). doi:10.1101/2021.03.08.21252807.
- 455 25. Sepúlveda N, Stresman G, White MT, Drakeley CJ. Current mathematical models for analyzing
- anti-malarial antibody data with an eye to malaria elimination and eradication. *Journal of Immunology*
- 457 Research **2015** (2015) 1–21. doi:10.1155/2015/738030.
- 458 26. Scheibenbogen C, Freitag H, Blanco J, Capelli E, Lacerda E, Authier J, et al. The European ME/CFS
- Biomarker Landscape project: an initiative of the European network EUROMENE. Journal of
- 460 translational medicine **15** (2017) 162. doi:https://doi.org/10.1186/s12967-017-1263-z.
- 461 27. Schork NJ, Murray SS, Frazer KA, Topol EJ. Common vs. rare allele hypotheses for complex diseases.
- 462 Current Opinion in Genetics & Development 19 (2009) 212–219. doi:10.1016/j.gde.2009.04.010.
- **28**. Gibson G. Rare and common variants: twenty arguments. *Nature Reviews Genetics* **13** (2012) 135–145. doi:10.1038/nrg3118.
- 465 29. Herrera S, de Vega WC, Ashbrook D, Vernon SD, McGowan PO. Genome-epigenome interactions
- associated with myalgic encephalomyelitis/chronic fatigue syndrome. *Epigenetics* **13** (2018) 1174–1190.
- doi:10.1080/15592294.2018.1549769.
- 468 30. Tanigawa Y, Li J, Justesen JM, Horn H, Aguirre M, DeBoever C, et al. Components of genetic
- associations across 2,138 phenotypes in the UK Biobank highlight adipocyte biology. *Nature*
- 470 *Communications* **10** (2019). doi:10.1038/s41467-019-11953-9.
- 471 31. Dibble JJ, McGrath SJ, Ponting CP. Genetic risk factors of ME/CFS: a critical review. Human
- 472 *Molecular Genetics* **29** (2020) R117–R124. doi:10.1093/hmg/ddaa169.
- 473 32. Hajdarevic R, Lande A, Mehlsen J, Rydland A, Sosa DD, Strand EB, et al. Genetic association study
- in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci.
- 475 Brain, Behavior, and Immunity **102** (2022) 362–369. doi:10.1016/j.bbi.2022.03.010.
- 476 33. Paulino CD, Soares P, Neuhaus J. Binomial regression with misclassification. *Biometrics* 59 (2003)
- 477 670–675. doi:10.1111/1541-0420.00077.

- 478 **34**. Luo S, Chan W, Detry MA, Massman PJ, Doody RS. Binomial regression with a misclassified covariate and outcome. *Statistical Methods in Medical Research* **25** (2012) 101–117. doi:10.1177/ 0962280212441965.
- 481 **35**. Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, et al. Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. *Nature Genetics* **51** (2018) 51–62. doi:10.1038/s41588-018-0303-9.
- 36. International Multiple Sclerosis Genetics Consortium (IMSGC). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nature Genetics* 45 (2013) 1353–1360. doi:10.1038/ng.2770.
- 37. Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals
 high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science* 375 (2022) 296–301.
 doi:10.1126/science.abj8222.
- 490 **38**. Pheby DFH, Araja D, Berkis U, Brenna E, Cullinan J, de Korwin JD, et al. A literature review of GP knowledge and understanding of ME/CFS: A report from the socioeconomic working group of the European network on ME/CFS (EUROMENE). *Medicina* **57** (2020) 7. doi:10.3390/medicina57010007.
- 39. Lacerda EM, Mudie K, Kingdon CC, Butterworth JD, O'Boyle S, Nacul L. The UK ME/CFS Biobank:
 A disease-specific biobank for advancing clinical research into myalgic encephalomyelitis/chronic fatigue syndrome. *Frontiers in Neurology* 9 (2018). doi:10.3389/fneur.2018.01026.
- 40. Dimmock ME, Mirin AA, Jason LA. Estimating the disease burden of ME/CFS in the United States
 and its relation to research funding. *Journal of Medicine and Therapeutics* 1 (2016). doi:10.15761/jmt.
 1000102.
- 499 **41**. Mirin AA, Dimmock ME, Jason LA. Research update: The relation between ME/CFS disease burden and research funding in the USA. *Work* **66** (2020) 277–282. doi:10.3233/WOR-203173.
- 42. Mirin AA, Dimmock ME, Jason LA. Updated ME/CFS prevalence estimates reflecting post-COVID increases and associated economic costs and funding implications. *Fatigue: Biomedicine, Health & Behavior* (2022) 1–11. doi:10.1080/21641846.2022.2062169.
- 504 **43**. Smith AK, Fang H, Whistler T, Unger ER, Rajeevan MS. Convergent genomic studies identify association of GRIK2 and NPAS2 with chronic fatigue syndrome. *Neuropsychobiology* **64** (2011) 183–194. doi:10.1159/000326692.
- 44. Hunter-Zinck H, Shi Y, Li M, Gorman BR, Ji SG, Sun N, et al. Genotyping array design and data quality control in the Million Veteran Program. *The American Journal of Human Genetics* 106 (2020) 535–548. doi:10.1016/j.ajhg.2020.03.004.
- 45. Hajdarevic R, Lande A, Rekeland I, Rydland A, Strand EB, Sosa DD, et al. Fine mapping of the major
 histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
- suggests involvement of both HLA class I and class II loci. *Brain, Behavior, and Immunity* **98** (2021) 101–109. doi:10.1016/j.bbi.2021.08.219.
- 46. Ariza ME. Commentary: Antibodies to human herpesviruses in myalgic encephalomyelitis/chronic
 fatigue syndrome patients. *Frontiers in Immunology* 11 (2020). doi:10.3389/fimmu.2020.01400.
- 47. Sepúlveda N, Malato JT, Sotzny F, Grabowska AD, Fonseca A, Cordeiro C, et al. Revisiting IgG
 antibody reactivity to Epstein-Barr virus in myalgic encephalomyelitis/chronic fatigue syndrome and
 its potential application to disease diagnosis. *medRxiv* (2022). doi:10.1101/2022.04.20.22273990.
- 48. Szklarski M, Freitag H, Lorenz S, Becker SC, Sotzny F, Bauer S, et al. Delineating the association
 between soluble CD26 and autoantibodies against G-protein coupled receptors, immunological and
 cardiovascular parameters identifies distinct patterns in post-infectious vs. non-infection-triggered

- 522 myalgic encephalomyelitis/chronic fatigue syndrome. *Frontiers in Immunology* **12** (2021). doi:10. 3389/fimmu.2021.644548.
- **49**. Malato J, Sotzny F, Bauer S, Freitag H, Fonseca A, Grabowska A, et al. The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome:
- A meta-analysis of public DNA methylation and gene expression data. *Heliyon* **7** (2021) e07665. doi:10.1016/j.heliyon.2021.e07665.
- 528 **50**. Cella M, Chalder T. Measuring fatigue in clinical and community settings. *Journal of Psychosomatic Research* **69** (2010) 17–22. doi:10.1016/j.jpsychores.2009.10.007.
- 530 **51**. Kaushik N. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. *Journal of Clinical Pathology* **58** (2005) 826–832. doi:10.1136/jcp.2005.025718.
- 532 52. Johnston S, Staines D, Klein A, Marshall-Gradisnik S. A targeted genome association study examining 533 transient receptor potential ion channels, acetylcholine receptors, and adrenergic receptors in chronic 534 fatigue syndrome/myalgic encephalomyelitis. *BMC Medical Genetics* 17 (2016). doi:10.1186/

535 s12881-016-0342-y.

- 53. Lande A, Fluge Ø, Strand EB, Flåm ST, Sosa DD, Mella O, et al. Human leukocyte antigen alleles
 associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Scientific Reports 10
 (2020). doi:10.1038/s41598-020-62157-x.
- 54. Blauensteiner J, Bertinat R, León LE, Riederer M, Sepúlveda N, Westermeier F. Altered endothelial dysfunction-related miRs in plasma from ME/CFS patients. *Scientific Reports* 11 (2021). doi:10.1038/s41598-021-89834-9.
- 55. de Vega WC, Vernon SD, McGowan PO. DNA methylation modifications associated with chronic fatigue syndrome. *PLoS ONE* **9** (2014) e104757. doi:10.1371/journal.pone.0104757.
- 56. Trivedi MS, Oltra E, Sarria L, Rose N, Beljanski V, Fletcher MA, et al. Identification of myalgic encephalomyelitis/chronic fatigue syndrome-associated DNA methylation patterns. *PLOS ONE* 13 (2018) e0201066. doi:10.1371/journal.pone.0201066.
- 57. Bo S, Ciccone G, Pearce N, Merletti F, Gentile L, Cassader M, et al. Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects. *Diabetes Research and Clinical Practice* 75 (2007) 362–365. doi:10.1016/j.diabres.2006.06.031.
- 58. Cabré JJ, Martín F, Costa B, Piñol JL, Llor JL, Ortega Y, et al. Metabolic syndrome as a cardiovascular disease risk factor: Patients evaluated in primary care. *BMC Public Health* 8 (2008). doi:10.1186/1471-2458-8-251.
- 59. Eftekharzadeh A, Asghari G, Serahati S, Hosseinpanah F, Azizi A, Barzin M, et al. Predictors of incident obesity phenotype in nonobese healthy adults. *European Journal of Clinical Investigation* 47 (2017) 357–365. doi:10.1111/eci.12743.
- 60. Maloney EM, Boneva RS, Lin JMS, Reeves WC. Chronic fatigue syndrome is associated with metabolic syndrome: results from a case-control study in Georgia. *Metabolism* 59 (2010) 1351–1357.
 doi:10.1016/j.metabol.2009.12.019.
- 559 **61**. Jason LA, Corradi K, Torres-Harding S, Taylor RR, King C. Chronic fatigue syndrome: The need for subtypes. *Neuropsychology Review* **15** (2005) 29–58. doi:10.1007/s11065-005-3588-2.
- 62. Kerr JR, Petty R, Burke B, Gough J, Fear D, Sinclair LI, et al. Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. *The Journal of Infectious Diseases* 197 (2008) 1171–1184. doi:10.1086/533453.
- 564 63. Zhang L, Gough J, Christmas D, Mattey DL, Richards SCM, Main J, et al. Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. *Journal of Clinical Pathology* 63 (2009) 156–164. doi:10.1136/jcp.2009.072561.

Malato et al.

Misdiagnosis in ME/CFS studies

64. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical
 Computing, Vienna, Austria (2020).

FIGURE CAPTIONS




Figure 1. Probabilities of rejecting the null hypothesis, i.e., absence of association between the two populations, as function of the misclassification rate. Each column represents the values attributed to the risk allele frequency found in matched healthy controls and false positive ME/CFS cases ($\theta_0 \in \{0.05, 0.1, 0.25, 0.5\}$). Each row varies the true odds ratio for the association between risk allele frequency assessed between true positive cases and healthy controls ($\Delta_T \in \{1.25, 1.5, 2, 3, 5, 10\}$). Power analysis was estimated for different sample sizes of 100, 250, 500, 1000, 2500, and 5000 ($n_0 = n_1$), represented by the different coloured lines on each scenario. Upper dashed line indicates the target power, where the probability of rejecting the null hypothesis is $1 - \beta = 0.80$. Lower dashed line indicates the significance level used, $\alpha = 0.05$.




Figure 2. Probabilities of rejecting H_0 as function of the misclassification rate. Each scenario represents simulated results with combination of serology test's sensitivity, π_{se} , and specificity, π_{sp} , for columns and rows, respectively. Power analysis was estimated for different sample sizes of 100, 250, 500, 1000, 2500, and 5000 ($n_0 = n_1$), represented by the different coloured lines on each scenario, with probability of exposure in healthy controls fixed as $\theta_0 = 0.25$ and true odds ratio $\Delta_T = 3$. Upper dashed line indicates the target power, where the probability of rejecting the null hypothesis is $1 - \beta = 0.80$. Lower dashed line indicates the significance level used, $\alpha = 0.05$.




Figure 3. Probabilities of rejecting the H_0 considering real-world data from (A) five different SNPs studied (genes PTPN22, CTLA4, TNF (1 and 2), and IRF5); and (B) six different human herpes viruses (CMV, EBV, HSV1 and HSV2, VZV, and HHV6), as function of misclassification rate. For each study, risk allele frequencies or probability of exposure and true odds ratio were determined by Steiner et al. (20) ($n_0 = 201$; $n_1 = 305$) and Cliff et al. (21) ($n_0 = 107$; $n_1 = 251$; $\pi_{se} = \pi_{sp} = 0.975$), with determined values shown in Tables 5 and 6, respectively. Green coloured lines indicate candidate risk factors where a significant association with the disease was found in the original study. Blue coloured lines show non-significant ME/CFS risk factors. Upper dashed line indicates the target power, where the probability of rejecting the null hypothesis is $1 - \beta = 0.80$. Lower dashed line indicates the significance level used, $\alpha = 0.05$.